ストックスクリーナーアプリを入手
9.66
2.55%
0.24
前日終値:
$9.42
開ける：
$9.72
24時間の取引高:
892.21K
Relative Volume:
1.15
時価総額：
$504.99M
収益：
$88.24M
当期純損益:
$-160.90M
株価収益率:
-3.6259
EPS:
-2.6642
ネットキャッシュフロー:
$-129.35M
1週間 パフォーマンス:
+9.34%
1か月 パフォーマンス:
+15.48%
6か月 パフォーマンス:
+11.16%
1年 パフォーマンス:
+136.19%
1日の値動き範囲:
$9.45
$9.97
1週間の範囲:
$8.548
$9.97
52週間の値動き範囲:
$3.68
$12.34
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
名前
4 D Molecular Therapeutics Inc
セクター
電話
(510) 505-2680
住所
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
9.66 | 504.99M | 88.24M | -160.90M | -129.35M | -2.6642 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-11-07 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | 開始されました | Morgan Stanley | Underweight |
| 2024-09-23 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | 開始されました | Barclays | Overweight |
| 2024-02-07 | 再開されました | Goldman | Buy |
| 2023-10-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-18 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 開始されました | Chardan Capital Markets | Buy |
| 2023-01-30 | 開始されました | BMO Capital Markets | Outperform |
| 2022-11-18 | 開始されました | H.C. Wainwright | Buy |
| 2022-11-15 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-12 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 開始されました | Jefferies | Buy |
| 2022-01-04 | 開始されました | SVB Leerink | Outperform |
| 2021-01-05 | 開始されました | BofA Securities | Buy |
| 2021-01-05 | 開始されました | Evercore ISI | Outperform |
| 2021-01-05 | 開始されました | Goldman | Neutral |
すべてを表示
4 D Molecular Therapeutics Inc (FDMT) 最新ニュース
4D Molecular Therapeutics (FDMT) director granted 50,000 stock options with CIC vesting - Stock Titan
4D Molecular (NASDAQ: FDMT) grants director 50,000 stock options - Stock Titan
4D Molecular Therapeutics (FDMT) director receives 50,000-share stock option grant - Stock Titan
4D Molecular (NASDAQ: FDMT) director gets 50,000 stock options grant - Stock Titan
4D Molecular Therapeutics (FDMT) grants director John F. Milligan 75,000 options - Stock Titan
4D Molecular (FDMT) grants director 50,000 stock options at $9.42 - Stock Titan
Director at 4D Molecular Therapeutics (NASDAQ: FDMT) receives 50,000 options - Stock Titan
Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape - The Manila Times
Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
4D Molecular Therapeutics Inc (FDMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
4D Molecular Therapeutics Inc (FDMT) Valuation: PE, PB & Fair Value Analysis - TradingKey
4D Molecular Therapeutics Inc (FDMT) Institutional Confidence - TradingKey
4D Molecular Therapeutics Inc (FDMT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
4D Molecular Therapeutics Inc (FDMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
4D Molecular Therapeutics Inc (FDMT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
4D Molecular Therapeutics Inc (FDMT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
4D Molecular Therapeutics Inc - TradingKey
4D Molecular Therapeutics Inc (FDMT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
4D Molecular Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
4DMT Announces New Employment Inducement Grants - GlobeNewswire
Fabry Disease Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutic - Barchart.com
Infographic: Study design for ELARA, an open-label, phase 3b trial of aflibercept 8 mg in previously treated patients with neovascular age-related macular degeneration or diabetic macular edema - Nature
FDMT: Gene therapy 4D-150 targets lifelong vision benefit and reduced injections in wet AMD - TradingView
FDMT: 4D-150 gene therapy shows promise for durable wet AMD treatment with strong safety and scalability - TradingView
Insider Sell Alert: David Kirn Sells Shares of 4D Molecular Therapeutics Inc (FDMT) - GuruFocus
4d molecular therapeutics CEO Kirn sells $19,257 in shares By Investing.com - Investing.com Australia
4d molecular therapeutics CEO Kirn sells $19,257 in shares - Investing.com
Insider David Kirn sells 1,922 4D Molecular (NASDAQ: FDMT) shares - Stock Titan
Monte Rosa (NASDAQ: GLUE) CEO sells 5,466 shares under Rule 10b5-1 plan - Stock Titan
[144] 4D Molecular Therapeutics, Inc. SEC Filing - Stock Titan
Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares under 10b5-1 plan - Stock Titan
Number of shareholders of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView
Opus Genetics Slides Ahead of June Test - Bez Kabli
IonQ Aktie: Two Sigma kauft 2,17 Millionen Aktien - Finanztrends
4D Molecular Therapeutics (FDMT) Gains 1.6% as Stock Holds Above SupportThematic ETF Flow - The Legal Advocate
4DMT to Participate in Upcoming Investor Conferences - The Globe and Mail
Pittsburgh Post-Gazette - FinancialContent
4D Molecular Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You? - Insider Monkey
4D Molecular Therapeutics, Inc.Common Stock (NQ: FDMT - FinancialContent
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
FDMT: Pivotal global trials advance a disruptive, lifelong gene therapy for retinal disease - TradingView
About Us - FinancialContent
User | mammothtimes.com4D Molecular Therapeutics, Inc.Common Stock (Nasdaq:FDMT) Stock Quote - FinancialContent
User | malvern-online.com4D Molecular Therapeutics, Inc.Common Stock (Nasdaq:FDMT) Stock Quote - FinancialContent
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy - MarketBeat
4D Molecular Therapeutics Inc. (FDMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
RA Capital affiliates report 9.99% of 4D Molecular (NASDAQ: FDMT) via warrants and shares - Stock Titan
BVF affiliates report 5.35M 4D shares (FDMT) and 8.48M pre-funded warrants - Stock Titan
Biotech 4D Molecular Therapeutics grants 141,100 RSUs to new employees - Stock Titan
Fat Pitch Financials4D Molecular Therapeutics, Inc.Common Stock (Nasdaq:FDMT) Stock Quote - FinancialContent
4 D Molecular Therapeutics Inc (FDMT) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):